Evidence map›Paper›PMID 32631176›Full record

SynthesisUnited European gastroenterology journal2020

The global prevalence of Barrett's esophagus: A systematic review of the published literature.

Inês Marques de Sá, Pedro Marcos, Prateek Sharma, Mário Dinis-Ribeiro

Abstract readSystematic Review
In one paragraph

Synthesis in United European gastroenterology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Barrett's esophagus: A review.World journal of gastrointestinal pathophysiology · 2025
    Review
  10. Article
  11. Article
  12. Computing lifetime incidence of esophageal adenocarcinoma and age-specific prevalence of Barrett's esophagus.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Cytosponge procedures produce fewer respiratory aerosols and droplets than esophagogastroduodenoscopies.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2024
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Inês Marques de SáDepartment of Gastroenterology, Portuguese Oncology Institute of Porto, Porto, Portugal.ORCID 0000-0001-8835-7183
Pedro MarcosDepartment of Gastroenterology, Centro Hospitalar de Leiria, Leiria, Portugal.
Prateek SharmaUniversity of Kansas School of Medicine, Kansas City, USA.
Mário Dinis-RibeiroDepartment of Gastroenterology, Portuguese Oncology Institute of Porto, Porto, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDetermining the prevalence of Barrett's esophagus is important for defining screening strategies. We aimed to synthesize the available data, determine Barrett's esophagus prevalence, and assess variability.

methodsThree databases were searched. Subgroup, sensitivity, and meta-regression analyses were conducted and pooled prevalence was computed.

resultsOf 3510 studies, 103 were included. In the general population, we estimated a prevalence for endoscopic suspicion of Barrett's esophagus of (a) any length with histologic confirmation of intestinal metaplasia as 0.96% (95% confidence interval: 0.85-1.07), (b) ≥1 cm of length with histologic confirmation of intestinal metaplasia as 0.96% (95% confidence interval: 0.75-1.18) and (c) for any length with histologic confirmation of columnar metaplasia as 3.89% (95% confidence interval: 2.25-5.54) . By excluding studies with high-risk of bias, the prevalence decreased to: (a) 0.70% (95% confidence interval: 0.61-0.79) and (b) 0.82% (95% confidence interval: 0.63-1.01). In gastroesophageal reflux disease patients, we estimated the prevalence with afore-mentioned criteria to be: (a) 7.21% (95% confidence interval: 5.61-8.81) (b) 6.72% (95% confidence interval: 3.61-9.83) and (c) 7.80% (95% confidence interval: 4.26-11.34). The Barrett's esophagus prevalence was significantly influenced by time period, region, Barrett's esophagus definition, Seattle protocol, and study design. There was a significant gradient East-West and North-South. There were minimal to no data available for several countries. Moreover, there was significant heterogeneity between studies.

conclusionThere is a need to reassess the true prevalence of Barrett's esophagus using the current guidelines in most regions. Having knowledge about the precise Barrett's esophagus prevalence, diverse attitudes from educational to screening programs could be taken.

Indexed as

Global Burden of DiseaseBarrett EsophagusData AccuracyDermatologyHumansPractice Guidelines as TopicPrevalenceResearch DesignBarrett metaplasiaepidemiologyprevalenceworldwide

Identifiers

PMID32631176
PMCPMC7724547

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.